| Good Samaritan Society Scotland | |
| 130 6th Street, Scotland, South Dakota 57059 | |
| (605) 583-2216 | |
| Name | Good Samaritan Society Scotland |
|---|---|
| Location | 130 6th Street, Scotland, South Dakota |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 37 |
| Occupancy Rate | 83.24% |
| Medicare ID (CCN) | 435095 |
| Legal Business Name | The Evangelical Lutheran Good Samaritan Society |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1417948704 |
| Organization Name | THE EVANGELICAL LUTHERAN GOOD SAMARITAN SOCIETY |
| Doing Business As | GOOD SAMARITAN SOCIETY - SCOTLAND |
| Address | 130 6th St, Scotland, SD 57059 |
| Phone Number | 605-583-2216 |
News Archive
Nov. 1 marks the start of Open Enrollment for people buying their own coverage for 2019 in most states. Despite the turmoil surrounding the Affordable Care Act, most consumers will have more choices and mostly flat — and in some cases lower — premiums.
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.
Eight candidates for the Democratic presidential nomination on Thursday in a debate at South Carolina State University "uniformly criticized" the U.S. Supreme Court's decision last week to uphold a federal law (S 3) banning so-called "partial-birth" abortion, the Washington Post reports (Balz, Washington Post , 4/27).
Vertex Pharmaceuticals Incorporated today announced positive results from the Phase 3 STRIVE study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.
› Verified 6 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Nov. 1 marks the start of Open Enrollment for people buying their own coverage for 2019 in most states. Despite the turmoil surrounding the Affordable Care Act, most consumers will have more choices and mostly flat — and in some cases lower — premiums.
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, today announces the successful Phase II enrollment of approximately ten patients of whom the majority have already been transplanted and received ATIR™. Kiadis Pharma's lead program, ATIR™, is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. Topline data from the trial (CR-AIR-007) is expected in the first half of 2014.
Eight candidates for the Democratic presidential nomination on Thursday in a debate at South Carolina State University "uniformly criticized" the U.S. Supreme Court's decision last week to uphold a federal law (S 3) banning so-called "partial-birth" abortion, the Washington Post reports (Balz, Washington Post , 4/27).
Vertex Pharmaceuticals Incorporated today announced positive results from the Phase 3 STRIVE study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 11.86 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 2.56 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 36.26 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.68 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 10.08 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.65 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 96.35 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 15.04 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 97.3 | 83.88 |